These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32324886)

  • 1. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia.
    van Vuren AJ; Eisenga MF; van Straaten S; Glenthøj A; Gaillard CAJM; Bakker SJL; de Borst MH; van Wijk R; van Beers EJ
    Blood Adv; 2020 Apr; 4(8):1678-1682. PubMed ID: 32324886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research.
    van Vuren AJ; Gaillard CAJM; Eisenga MF; van Wijk R; van Beers EJ
    Front Physiol; 2019; 10():304. PubMed ID: 30971944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
    Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
    Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis.
    Iwasaki T; Fujimori A; Nakanishi T; Okada S; Hanawa N; Hasuike Y; Kuragano T
    BMC Nephrol; 2021 Apr; 22(1):124. PubMed ID: 33832448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans.
    Bielesz B; Reiter T; Hammerle FP; Winnicki W; Bojic M; Gleiss A; Kieweg H; Ratzinger F; Sunder-Plassmann G; Marculescu R
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32823844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
    PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
    Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
    PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-terminal fragment of fibroblast growth factor 23 improves heart function in murine models of high intact fibroblast growth factor 23.
    Hu MC; Reneau JA; Shi M; Takahashi M; Chen G; Mohammadi M; Moe OW
    Am J Physiol Renal Physiol; 2024 Apr; 326(4):F584-F599. PubMed ID: 38299214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23.
    Roszko KL; Brown S; Pang Y; Huynh T; Zhuang Z; Pacak K; Collins MT
    J Bone Miner Res; 2021 Feb; 36(2):315-321. PubMed ID: 33049075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interconnections of fibroblast growth factor 23 and klotho with erythropoietin and hypoxia-inducible factor.
    Afsar B; Kanbay M; Afsar RE
    Mol Cell Biochem; 2022 Jul; 477(7):1973-1985. PubMed ID: 35381946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
    Noonan ML; Ni P; Agoro R; Sacks SA; Swallow EA; Wheeler JA; Clinkenbeard EL; Capitano ML; Prideaux M; Atkins GJ; Thompson WR; Allen MR; Broxmeyer HE; White KE
    J Bone Miner Res; 2021 Jun; 36(6):1117-1130. PubMed ID: 33592127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High intact fibroblast growth factor 23 levels associated with low hemoglobin levels in patients on chronic hemodialysis.
    Fang YW; Wang JT; Lin TY; Lee CJ; Jang TN; Tsai MH; Liou HH
    Front Med (Lausanne); 2023; 10():1098871. PubMed ID: 37081846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans.
    Sharma S; Katz R; Ginsberg C; Bullen A; Vallon V; Thomson S; Moe OW; Hoofnagle AN; de Leeuw PW; Kroon AA; Houben AJHM; Ix JH
    J Bone Miner Res; 2022 Jun; 37(6):1170-1178. PubMed ID: 35373859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipients.
    Limm-Chan B; Wesseling-Perry K; Pearl MH; Jung G; Tsai-Chambers E; Weng PL; Hanudel MR
    Pediatr Nephrol; 2021 Oct; 36(10):3241-3249. PubMed ID: 33903951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
    Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men.
    Daryadel A; Bettoni C; Haider T; Imenez Silva PH; Schnitzbauer U; Pastor-Arroyo EM; Wenger RH; Gassmann M; Wagner CA
    Pflugers Arch; 2018 Oct; 470(10):1569-1582. PubMed ID: 29961920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
    Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
    Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EPO-dependent induction of erythroferrone drives hepcidin suppression and systematic iron absorption under phenylhydrazine-induced hemolytic anemia.
    Jiang X; Gao M; Chen Y; Liu J; Qi S; Ma J; Zhang Z; Xu Y
    Blood Cells Mol Dis; 2016 May; 58():45-51. PubMed ID: 27067488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Erythroferrone During Pregnancy Is Related to Erythropoietin but Does Not Predict the Risk of Anemia.
    Delaney KM; Guillet R; Pressman EK; Ganz T; Nemeth E; O'Brien KO
    J Nutr; 2021 Jul; 151(7):1824-1833. PubMed ID: 33982118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.